Veru ( NASDAQ: VERU ) is a late-clinical-stage biopharma company emerging from a comprehensive restructuring effort in 2024. After divesting its commercial sexual health business for $18 million in 2024, Veru has pivoted toward an entirely new Analyst's Disclosure: I/we have a beneficial long position in the shares of VERU either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeki ...